Following publication, the authors conducted additional experiments to determine the genetic background of PKR regulatory domain mutant mice used in this study [1], and in a related article demonstrated that some phenotypes were not replicated when using a different PKR mutant line on a different genetic background [2].

• The genetic background of the PKR regulatory domain mutant mice was not known to the authors at the time the in vivo experiments were conducted for the PLOS ONE article, and so was not reported [1]. Following the publication of this work, the authors conducted SNP genotyping analyses and determined that PKR regulatory domain mutant mice used in the experiments were on a 98.9% 129S1/SvImJ genetic background. Hence, for some of the experiments reported in the PLOS ONE article, the genetic background is different between mutant and control animals (Figures 1–5).

• Following publication of the PLOS ONE article [1], the authors repeated experiments in vitro using bone-marrow derived macrophages and in vivo in a mouse model of tuberculosis infection using a different PKR-deficient mouse line harboring a catalytic domain mutation [3] instead of a regulatory domain mutation [4]. In these follow-up experiments, both mutant and control animals were on a C57Bl/6J background. These experiments yielded different results than those reported in the PLOS ONE article: the authors did not observe a statistically significant difference in CFU in lung between WT and PKR-deficient mice in the mouse model of Mtb infection, as reported in detail in [2]. While these findings did not support the conclusions of the PLOS ONE article, they were not based on exact experimental replications, as noted in the following table.

Download:

• PPT
  PowerPoint slide
• PNG
  larger image
• TIFF
  original image

https://doi.org/10.1371/journal.pone.0205424.t001

• The differences between the PLOS ONE and EJI experiments are tabulated above. The macrophage experiments in PLOS ONE article [1] used WT mice on a C57BL/6J background and regulatory domain PKR KO mice on a 129S1/SvImJ background. The macrophage experiments in the EJI article [2] used WT mice on a C57BL/6J background and both regulatory domain and catalytic domain PKR KO mice, each on a C57BL/6J background, and observed that PKR sufficiency or deficiency did not impact macrophage activation. The EJI article also compared WT mice on a 129S1/SvImJ background and regulatory domain PKR KO mice on a 129S1/SvImJ background, similar to the mice used in [1], and observed that interferon-gamma alone caused macrophage activation to similar levels in both WT and mutant, suggesting that heightened macrophage activation could be a background effect. In the EJI article it was observed that there was no statistically significant difference in Mtb CFU burden between WT and catalytic domain PKR KO mice, both on the C57BL/6J background. The EJI study casts doubt on the candidacy of PKR as a target for HDT of TB.